These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2142231)

  • 1. Review of the pharmacological properties of toremifene.
    Kangas L
    J Steroid Biochem; 1990 Jun; 36(3):191-5. PubMed ID: 2142231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat.
    di Salle E; Zaccheo T; Ornati G
    J Steroid Biochem; 1990 Jun; 36(3):203-6. PubMed ID: 2142233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.
    Kangas L; Nieminen AL; Blanco G; Grönroos M; Kallio S; Karjalainen A; Perilä M; Södervall M; Toivola R
    Cancer Chemother Pharmacol; 1986; 17(2):109-13. PubMed ID: 2941177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
    Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
    Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and pharmacological effects of toremifene metabolites.
    Kangas L
    Cancer Chemother Pharmacol; 1990; 27(1):8-12. PubMed ID: 2147128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new triphenylethylene compound, Fc-1157a. I. Hormonal effects.
    Kallio S; Kangas L; Blanco G; Johansson R; Karjalainen A; Perilä M; Pippo I; Sundquist H; Södervall M; Toivola R
    Cancer Chemother Pharmacol; 1986; 17(2):103-8. PubMed ID: 2941176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
    Mäenpää JU; Ala-Fossi SL
    Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse.
    Robinson SP; Jordan VC
    Cancer Res; 1989 Apr; 49(7):1758-62. PubMed ID: 2522347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women.
    Mäenpää J; Söderström KO; Grönroos M; Taina E; Hajba A; Kangas L
    J Steroid Biochem; 1990 Jun; 36(3):221-3. PubMed ID: 2142237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to toremifene.
    Kangas L
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S3-7. PubMed ID: 2149282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
    Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2.
    Robinson SP; Goldstein D; Witt PL; Borden EC; Jordan VC
    Breast Cancer Res Treat; 1990 Feb; 15(2):95-101. PubMed ID: 2138919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive and synergistic antitumor effects with toremifene and interferons.
    Kangas L; Cantell K; Schellekens H
    J Steroid Biochem; 1990 Jun; 36(3):259-62. PubMed ID: 2142249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of toremifene on the activity of NK-cells in NZB/NZW mice.
    Wärri A; Kangas L
    J Steroid Biochem; 1990 Jun; 36(3):207-9. PubMed ID: 2142234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study.
    Gundersen S
    J Steroid Biochem; 1990 Jun; 36(3):233-4. PubMed ID: 2142241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
    Jordan VC; Gosden B
    Endocrinology; 1983 Aug; 113(2):463-8. PubMed ID: 6872937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bioassay for antiestrogenic activity--potential utility in drug development and monitoring effective in vivo dosing.
    DeGregorio M; Wurz G; Emshoff V; Koester S; Minor P; Wiebe V
    Breast Cancer Res Treat; 1992; 24(1):35-41. PubMed ID: 1463870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo binding of toremifene and its metabolites in rat uterus.
    Simberg NH; Murai JT; Siiteri PK
    J Steroid Biochem; 1990 Jun; 36(3):197-202. PubMed ID: 2142232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.
    Carthew P; Edwards RE; Nolan BM
    Toxicol Appl Pharmacol; 1999 Jul; 158(1):24-32. PubMed ID: 10387929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compartmentalized uterotrophic effects of tamoxifen, toremifene, and estradiol in the ovariectomized Wistar (Han) rat.
    Carthew P; Edwards RE; Nolan BM; Tucker MJ; Smith LL
    Toxicol Sci; 1999 Apr; 48(2):197-205. PubMed ID: 10353311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.